Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Vilobelimab by InflaRx for Pyoderma Gangrenosum: Likelihood of Approval
Vilobelimab is under clinical development by InflaRx and currently in Phase III for Pyoderma Gangrenosum. According to GlobalData, Phase III...